TABLE 1.
Maximum (peak) FLU‐PRO Chest/Respiratory score during the first 7 days from the onset of the first RT‐PCR‐confirmed RSV‐ARI episode (mES RT‐PCR‐confirmed RSV‐ARI cohort).
| Characteristic |
RSVPreF3 OA N = 27 |
Placebo N = 95 |
p value |
|---|---|---|---|
| Chest/respiratory | |||
| N with data | 24 | 76 | |
| Median | 1.07 | 1.86 | 0.0258 |
| Q1–Q3 | 0.29–2.21 | 1.43–2.50 | |
| Mean (SD) | 1.32 (1.02) | 1.90 (0.93) | |
| Upper respiratory | |||
| N with data | 24 | 76 | |
| Median | 1.59 | 1.40 | 0.7199 |
| Q1–Q3 | 0.80–2.20 | 1.10–1.94 | |
| Mean (SD) | 1.56 (0.88) | 1.49 (0.73) | |
Note: A higher score indicates a higher level of symptoms severity.
Abbreviations: FLU‐PRO, InFLUenza Patient‐Reported Outcome; mES, modified exposed set; N, number of first RT‐PCR‐confirmed RSV‐ARI episodes; Placebo, participants receiving placebo; Q1, 25th percentile; Q3, 75th percentile; RSV‐ARI, respiratory syncytial virus–acute respiratory infection; RSVPreF3 OA, participants receiving RSVPreF3 OA vaccine; RT‐PCR, reverse transcription polymerase chain reaction; SD, standard deviation.